KNOXVILLE, TN, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled “Halogenated Xanthenes as Vaccine Adjuvants.” The allowed patent application covers the use of Provectus’s pharmaceutical-grade rose bengal sodium (RBS) drug substance as an adjuvant in anticancer, antiviral, and possibly other vaccines to potentially make them work better by enhancing T-cell response.

田纳西州诺克斯维尔，2023年12月18日（环球通讯社）--Provectus（OTCQB:PVCT）今天宣布，美国专利和商标局（USPTO）已批准专利申请17/488430，标题为“卤代黄嘌呤作为疫苗佐剂”。“允许的专利申请包括使用普罗维特斯的药物级孟加拉玫瑰钠（RBS）药物作为抗癌，抗病毒和可能的其他疫苗的佐剂，以通过增强T细胞反应使其更好地发挥作用。

The allowed application would be Provectus’s first patent award in the field of vaccines from the USPTO. Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee. Aru Narendran, MD, PhD, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology and Physiology and Pharmacology at the University’s Cumming School of Medicine is a co-inventor.

允许的申请将是美国专利商标局（USPTO）授予普罗维特斯疫苗领域的第一项专利。加拿大阿尔伯塔省卡尔加里大学的创新公司Innovate Calgary是共同受让人。阿鲁·纳伦德兰（Aru Narendran），医学博士，博士，该大学卡明医学院（Cumming School of Medicine）儿科，肿瘤学，生物化学和分子生物学以及生理学和药理学教授，是共同发明人。

The research underlying the allowed application was led by Dr. Narendran and his lab team (the Narendran Lab). Preclinical data from ongoing research on the potential use of investigational cancer immunotherapy PV-10 (rose bengal sodium) as a vaccine adjuvant was the subject of a poster presentation by the Narendran Lab at the Society for Immunotherapy of Cancer (SITC) 2023 annual meeting.

允许应用的基础研究由Narendran博士和他的实验室团队（Narendran实验室）领导。Narendran实验室在癌症免疫治疗学会（SITC）2023年年会上发布的海报主题是正在进行的关于研究性癌症免疫疗法PV-10（玫瑰红孟加拉钠）作为疫苗佐剂的潜在用途的研究的临床前数据。

A copy of the SITC 2023 poster, titled “The iodinated fluorescein derivative PV-10 enhances the antiviral activity of CD8+ T-Cells by inducing STING dimerization: Implications for enhanced vaccine applications,” is available on Provectus’s website at https://www.provectusbio.com/media/docs/2023-SITC-poster.pdf.

SITC 2023海报的副本，题为“碘化荧光素衍生物PV-10通过诱导STING二聚化增强CD8+T细胞的抗病毒活性：对增强疫苗应用的影响”，可在Provectus的网站上获得https://www.provectusbio.com/media/docs/2023-sitc-poster.pdf.

The Narendran Lab previously discovered that PV-10 activated stimulator of interferon (IFN) genes (STING), demonstrating its potential as a vaccine adjuvant in PV-10-mediated systemic an.

Narendran实验室先前发现PV-10激活干扰素（IFN）基因刺激物（STING），证明其在PV-10介导的系统性an中作为疫苗佐剂的潜力。